The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211

Authors :: D. Robesti
L. Nocera
F. Belladelli
J.G. Schultz
G. Fallara
L. Marandino
D. Raggi
F. Montorsi
A. Necchi
A. Martini
Source :: European Urology. 83:S763-S764
Publication Year :: 2023
Publisher :: Elsevier BV, 2023.

Tools